Mayo Clinic | Strategic Alliance Partners

March 29, 2023

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

March 29, 2023

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

March 27, 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

March 27, 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

March 22, 2023

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

March 22, 2023

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

March 20, 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

March 20, 2023

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

March 13, 2023

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

March 13, 2023

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

March 07, 2023

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

March 06, 2023

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

March 06, 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

March 06, 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

March 03, 2023

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

March 03, 2023

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

February 27, 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

February 27, 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

February 20, 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

February 20, 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.